LONDON, England, Sept. 21 (TNSJou) -- The Institute of Cancer Research issued the following news release: A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice. Final results from the trial showed that olaparib - a pioneering type of drug called a PARP inhibitor and the first ever cancer drug to target an inherited genetic f  more

HOUSTON, Texas, Sept. 21 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 20: In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits. Results from the trial were published today in the New England Journal of Medicine and data from the lung cancer cohort also were presented at the European  more

WALTHAM, Massachusetts, Sept. 21 -- The New England Journal of Medicine, a peer-reviewed medical journal from the the Massachusetts Medical Society that says it delivers research and interactive clinical content to physicians, educators and the global medical community, published research articles, including the following topics, in its Sept. 17, 2020 edition: Perspective: * Consent to Trainee Involvement in Pediatric Care * June Medical Services v. Russo -- A Threat to Physicians' Standing   more

MIDDLETON, Wisconsin, Sept. 21 -- Wetlands, a journal that says it features wetlands biology, ecology, hydrology, water chemistry, soil and sediment characteristics, management, education, legislation, cultural, sociology and regulations from the Society for Wetland Scientists, published research articles on the following topics in its August 2020 edition: * Coastal Marsh Bird Habitat Selection and Responses to Hurricane Sandy * Denitrification Capacity of Hill Country Wet and Dry Area Soils a  more